Cervical adenocarcinoma has good survival rates when caught, treated early

Cervical adenocarcinoma has at least a 50 percent survival rate which can be further improved by early diagnosis and individualized and comprehensive treatment, a recent study has found.

A total of 154 cervical adenocarcinoma patients participated in the study and were categorized according to clinical stage, as defined by the International Union of Gynaecology and Obstetrics. Other clinicopathological, treatment, and outcome data were also included.

Over a median follow-up time of 53 months, the researchers calculated a 5-year overall survival rate of 51.4 percent. This value was higher in patients who had stage I and II disease (67.6 percent and 59.8 percent, respectively), and lower in those with stage III cervical adenocarcinoma (19 percent). Among women with stage IV malignancy, 5-year survival rate was 0 percent. Eight patients were lost to follow-up.

Similarly, 5-year survival rate varied according to treatment method as well. Those who underwent surgery, for instance, had a nearly 20-percent survival advantage relative to those who received radical radiotherapy (61.6 percent vs 38.2 percent, respectively).

Interstitial infiltration likewise emerged as an important predictor such that patients with infiltration depth ≤10 mm vs >10 mm had better 5-year survival rates (69.1 percent vs 51.4 percent). Those with lymph node metastasis also saw worse 5-year survival rates (17.6 percent vs 74.3 percent).

Subsequent multifactor analysis confirmed that clinical disease stage (p<0.001) and lymph node metastasis (p<0.05) were significant predictors of 5-year survival in cervical adenocarcinoma. Lesion size (p=0.003) and interstitial infiltration depth (p=0.006) were significant only in single-factor analysis.